当前位置: X-MOL 学术Cancer J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic and Predictive Biomarkers in Oligometastatic Disease.
The Cancer Journal ( IF 2.2 ) Pub Date : 2020-03-01 , DOI: 10.1097/ppo.0000000000000438
Kevin J Barnum 1 , Sarah A Weiss
Affiliation  

Metastatic lesions are largely responsible for cancer-related deaths and are synonymous with a poor prognosis. However, this is not always true for patients with oligometastases whose disease may be amenable to curative-intent local therapies. It has been proposed that an “intermediate state” (oligometastasis) exists in between locoregional and advanced disease states; however, the clinical definition of oligometastasis varies, and there is limited understanding of how tumor biology differs between oligometastases and polymetastases. There is evidence that local therapies can extend survival in patients with oligometastases, yet patient selection for local intervention and/or systemic therapy remains a challenge. Prognostic and predictive biomarkers of oligometastatic disease are strongly needed to identify patient candidates most likely to gain survival benefit from local therapies and to aid in the incorporation of ablative treatments in the context of existing systemic therapies.

中文翻译:

寡转移性疾病的预后和预测性生物标志物。

转移性病变在很大程度上是导致癌症相关死亡的原因,并且是预后不良的代名词。然而,对于患有寡转移灶的患者来说,这并不总是正确的,他们的疾病可能会接受以治愈为目的的局部治疗。有人提出在局部区域和晚期疾病状态之间存在“中间状态”(寡转移);然而,寡转移的临床定义各不相同,并且对寡转移和多转移之间的肿瘤生物学差异的理解有限。有证据表明局部治疗可以延长寡转移患者的生存期但选择局部干预和/或全身治疗的患者仍然是一个挑战。预后强烈需要寡转移性疾病的预测性 生物标志物来识别最有可能从局部治疗中获得生存益处的患者候选人,并帮助在现有全身治疗的背景下结合消融治疗。
更新日期:2020-03-01
down
wechat
bug